JP2023532209A5 - - Google Patents

Info

Publication number
JP2023532209A5
JP2023532209A5 JP2022577703A JP2022577703A JP2023532209A5 JP 2023532209 A5 JP2023532209 A5 JP 2023532209A5 JP 2022577703 A JP2022577703 A JP 2022577703A JP 2022577703 A JP2022577703 A JP 2022577703A JP 2023532209 A5 JP2023532209 A5 JP 2023532209A5
Authority
JP
Japan
Prior art keywords
approximately
compound
amount
weight
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022577703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532209A (ja
JP7802018B2 (ja
Filing date
Publication date
Priority claimed from PCT/CN2020/097036 external-priority patent/WO2021253380A1/en
Application filed filed Critical
Publication of JP2023532209A publication Critical patent/JP2023532209A/ja
Publication of JP2023532209A5 publication Critical patent/JP2023532209A5/ja
Application granted granted Critical
Publication of JP7802018B2 publication Critical patent/JP7802018B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022577703A 2020-06-19 2021-06-18 経口製剤およびその用途 Active JP7802018B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2020/097036 WO2021253380A1 (en) 2020-06-19 2020-06-19 Oral formulations and uses thereof
CNPCT/CN2020/097036 2020-06-19
PCT/CN2021/100806 WO2021254471A1 (en) 2020-06-19 2021-06-18 Oral formulations and uses thereof

Publications (3)

Publication Number Publication Date
JP2023532209A JP2023532209A (ja) 2023-07-27
JP2023532209A5 true JP2023532209A5 (cg-RX-API-DMAC10.html) 2024-06-18
JP7802018B2 JP7802018B2 (ja) 2026-01-19

Family

ID=79268491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022577703A Active JP7802018B2 (ja) 2020-06-19 2021-06-18 経口製剤およびその用途

Country Status (9)

Country Link
US (1) US20230263782A1 (cg-RX-API-DMAC10.html)
EP (1) EP4168011B1 (cg-RX-API-DMAC10.html)
JP (1) JP7802018B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230026415A (cg-RX-API-DMAC10.html)
CN (1) CN115996723A (cg-RX-API-DMAC10.html)
AU (1) AU2021291257A1 (cg-RX-API-DMAC10.html)
CA (1) CA3179791A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022016118A (cg-RX-API-DMAC10.html)
WO (2) WO2021253380A1 (cg-RX-API-DMAC10.html)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004175795A (ja) 2002-11-13 2004-06-24 Takeda Chem Ind Ltd 薬物の放出性に優れた医薬組成物
TW200803850A (en) 2006-03-06 2008-01-16 Wyeth Corp Tablet formulations and processes
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
AP2015008858A0 (en) * 2013-05-28 2015-11-30 Astrazeneca Ab Chemical compounds
CN109362222B (zh) 2016-02-05 2021-03-19 益方生物科技(上海)股份有限公司 选择性雌激素受体降解物及其用途
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
MA46563B1 (fr) 2016-10-24 2024-01-31 Janssen Sciences Ireland Unlimited Co Compositions dispersibles
WO2018130124A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
CN108864080B (zh) * 2017-05-09 2021-10-15 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的四环类化合物及其应用
JP7448541B2 (ja) 2018-12-24 2024-03-12 インベンティスバイオ カンパニー リミテッド 選択的エストロゲン受容体分解剤の新規な塩

Similar Documents

Publication Publication Date Title
CN102724970B (zh) 来那替尼马来酸盐的片剂制剂
RU2485947C2 (ru) Фармацевтические композиции энтакапона, леводопы и карбидопы с улучшенной биодоступностью
JP6173521B2 (ja) ナルブフィンを含有する製剤及びそれらの使用
TW473392B (en) Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
CN1358090A (zh) 左旋多巴/卡比多巴/恩他卡朋药物制剂
UA74164C2 (uk) Фармацевтична композиція ліків проти туберкульозу і спосіб її одержання
TWI700100B (zh) 用於口服投藥之包含依澤替米貝(ezetimibe)及羅舒伐他汀(rosuvastatin)的複合調配物及其製備方法
JP2017537899A5 (cg-RX-API-DMAC10.html)
WO2008064202A2 (en) Modified-release formulations of calcium receptor-active compounds
CN104661649A (zh) 包含替格瑞洛的固态口服医药制剂
JP2022535893A5 (cg-RX-API-DMAC10.html)
AU2019232937B2 (en) Ceritinib formulation
CN101312714A (zh) 替米沙坦的药用组合物
WO2009084041A4 (en) Pharmaceutical compositions of dexibuprofen
TWI608849B (zh) 可調控釋放度之高載藥量之醫藥組合物及其製備方法
JP2017075139A (ja) 低用量薬物を含有する口腔内崩壊錠
JP7023600B2 (ja) シロドシン含有医薬組成物とその製造方法
JP2019194221A (ja) 医薬製剤
JPWO2011081118A1 (ja) 経口投与用医薬組成物
JP7330948B2 (ja) トシル酸スプラタストを含む組成物
JP2023553274A (ja) ドフェチリド及びメキシレチンを含有する組成物並びにその使用
WO2019008426A1 (en) NOVEL ENZALUTAMIDE ORAL GALENIC FORM COMPOSITION AND METHOD OF MANUFACTURING THE SAME
JP2023516358A (ja) キナーゼ阻害剤の医薬組成物
JP2019503373A (ja) キノリン誘導体またはその塩を含有する医薬組成物の製造方法
WO2025209440A1 (zh) 一种吡啶酮衍生物的药物组合物及其应用